BIOCRYST PHARMACEUTICALS INC — Director's Dealing 2017

Sep 5, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK: 0000882796
Period of Report: 2017-08-31

Reporting Person: Stonehouse Jon P (Director, President & CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-08-31	Emp. Stock Option (Right to Buy)	$12.16	A	40710	Acquired	2025-01-01	Common Stock (40710)	Direct

Footnotes

F1: On August 30, 2017, the Science Committee of the Board of Directors determined that the BCX7353 APeX-1 clinical trial met its goals and BCX7353 warrants further development. As a result, on August 31, 2017, the Compensation Committee of the Board of Directors determined that one of the vesting criteria associated with the performance-based stock options awarded to the reporting person in January 2015 has been met. Therefore, 30% of the performance-based stock options vested on August 31, 2017.